First in-human study update – webcast presentation

Jun 24, 2020
Posted in: Investor updates, Press & Media

Home » First in-human study update – webcast presentation

First in-human study update – webcast presentation

Jun 24, 2020
Posted in: Investor updates, Press & Media

You can also register to watch the entire Zoom webcast on-demand by clicking here

Imagion Biosystems HER2 Breast Cancer Program Update

October 7, 2025

Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,

Imagion Biosystems EGM Chairman’s Address

September 24, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Pitt Street Research – “Detecting cancers earlier” with Imagion Biosystems

September 11, 2025

Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2. Abstract: MagSense is a

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

First in-human study update – webcast presentation

First in-human study update – webcast presentation

Related Articles

Imagion Biosystems HER2 Breast Cancer Program Update

Imagion Biosystems EGM Chairman’s Address

Pitt Street Research – “Detecting cancers earlier” with Imagion Biosystems

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list